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(vs. warfarin), and apixaban (vs. aspirin) to be cost-effective; data on
clopidogrelaspirin (vs. aspirin) to be conflicting, and genotyped-warfarin and xi-
melagtran not cost-effective. CONCLUSIONS: Cost-effectiveness models of pharma-
cologic SPAF have been extensively published; but none have estimated the comparative
cost-effectiveness of newer agents. Models used similar structures and non-drug-specific
inputs, and commonly find innovator strategies to be cost-effective.
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OBJECTIVES: To undertake an economic evaluation of rivaroxaban relative to the
local standard of care, acenocoumarol, for stroke prevention in atrial fibrillation
(AF) patients with one or more risk factors.METHODS:A Markov model designed to
reflect the natural progression of AF patients through different health states was
developed and adapted to the Greek setting. The analysis was undertaken from a
payer perspective. Baseline event rates (adjusted to three month cycles) and rela-
tive treatment effects (RRs) were derived from the safety on treatment analysis of
the ROCKET AF study. Utility values for events were based on literature. A treat-
ment-related disutility of 0.05 was applied to acenocoumarol arm. Costs assigned
to each health state reflect local drug acquisition, monitoring, event management
and transportation costs and reflect the year 2012. An incremental cost effective-
ness ratio (ICER) per quality-adjusted-life year (QALY) gained was calculated. One-
way sensitivity analyses were conducted to identify key model drivers. Probabilis-
tic analysis was undertaken to deal with uncertainty. The horizon of analysis was
over patient life time and both cost and outcomes were discounted at 3.5%.
RESULTS: The average total cost of rivaroxaban-treated patients was €985 higher
compared to acenocoumarol. Rivaroxaban was associated with additional drug
acquisition costs (€5,275), however these were mainly offset by reduced monitoring
(€3,947) and event costs (€343). Moreover, rivaroxaban was associated with a 0.22
increment in QALYs leading to an ICER of €4,517/QALY gained. Sensitivity analyses
showed that the cost-effectiveness results are fairly robust with discontinuation
rate of rivaroxaban, acenocoumarol monitoring visits, acenocoumarol-related util-
ity decrement, RR for rivaroxaban versus acenocoumarol for stroke having the
highest impact on results. Probabilistic analysis revealed a high probability of ri-
varoxaban being cost-effective at a threshold of €30,000 or €40,000/QALY.
CONCLUSIONS: Rivaroxaban may represent a cost-effective option for the preven-
tion of stroke in AF patients with one or more risk factors.
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OBJECTIVES: In the PLATO study, ticagrelor significantly reduced the rate of myo-
cardial infarction (MI), stroke, or death from vascular causes without a significant
increase in the rate of overall major bleeding compared to Clopidogrel in the man-
agement of acute coronary syndrome (ACS) patients. We aimed to assess the long
term cost-effectiveness of ticagrelor versus clopidogrel in the management of ACS
patients in Hong Kong. METHODS: A Markov decision analytic model was used to
perform a cost-effectiveness analysis (CEA) of treating ACS patients for one year
with ticagrelor plus aspirin (group 1) compared with clopidogrel plus aspirin (group
2) from the Hong Kong health care provider perspective. The model simulates a
cohort of 45-year-old patients with ACS moving between different health status in
each Markov cycle of 1 year. The time horizon was lifetime (85 years old). Health
states included patient in ACS without event, myocardial infarction (MI), and death
from vascular cause. Outcome measures included lifetime costs, quality-adjusted
life years (QALYs) gained and incremental cost-effectiveness ratios (ICERs). Event
rates of group 1 are adopted from the PLATO study and rates of group 2 from the
Prince of Wales Hospital ACS Registry in Hong Kong. Probabilistic sensitivity anal-
yses using Monte Carlo simulations were conducted to assess parameter
uncertainty. RESULTS: The ICER for ticagrelor compared to clopidogrel in the treat-
ment of ACS was HK$34,441 (US$4,415) per QALY gained. For the subset of patients
with ST elevation myocardial infarction (STEMI) and non-ST elevation ACS
(NSTEACS), the ICERs per QALY gained were HK$ 33,402 (US$4,282) and HK$ 38,844
(4,980) respectively. Ticagrelor treatment strategy was cost-effective over 99% of
the Monte Carlo simulation using a cost-effectiveness threshold of 3 times gross
domestic product (GDP) per capita in Hong Kong. CONCLUSIONS: The treatment of
ACS patients with ticagrelor for 12 months is considered cost-effective compared
with clopidogrel from a health care provider perspective.
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OBJECTIVES: To evaluate the cost-effectiveness of the once daily oral anticoagu-
lant rivaroxaban for prevention of stroke and systemic embolism in non-valvular
atrial fibrillation (NVAF) patients from a UK payer perspective. METHODS: A
Markov model was developed to evaluate cost-effectiveness over a lifetime time
horizon. Costs and benefits were discounted at 3.5%. The patient population of
interest were AF patients with one or more risk factors currently treated with
warfarin. Clinical inputs were supplied from Safety-on-Treatment data from the
Phase III ROCKET trial or informed by systematically reviewed literature. The In-
tention-to-Treat (ITT) dataset was also used in a sensitivity analysis. Warfarin
efficacy data was adjusted to be reflective of the level of INR control found in
Western Europe and baseline risk was adjusted to be reflective of the UK popula-
tion. Economic inputs were based on unit costs from the BNF, PSSRU and NHS
Reference costs and resource use was from a dedicated observational study. Utility
inputs were taken from a systematic review and included baseline utilities for AF,
disutilities for clinical events and warfarin treatment. RESULTS: Base case analysis
versus warfarin resulted in a total per patient incremental cost of £705 and an
incremental QALY gain of 0.2459 with an estimated ICER of £2,869. The ITT analysis
returned an ICER of £3,404, with an incremental cost of £775 and an incremental
QALY of 0.2277. The sensitivity analyses found that the biggest drivers of the result
were discontinuation rates, warfarin monitoring cost in primary care, warfarin
disutility and frequency of warfarin monitoring. The PSA indicates that the prob-
ability of rivaroxaban being cost-effective at a willingness-to-pay threshold of
£20,000 is 97%. CONCLUSIONS: Rivaroxaban is a cost-effective alternative to war-
farin in the prevention of stroke and systemic embolism in NVAF patients with one
or more risk factors as evaluated from a UK payer perspective.
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OBJECTIVES: Statin monotherapy is the mainstay of LDL-C management for CHD
patients in Portugal, however several therapeutic options are available and pre-
dicted to have different clinical and economical impact. This analysis estimates the
Cost-Effectiveness (CE) of adding ezetimibe 10 mg (EZ10) to generic atorvastatin
10/20 mg (A10/20) against generic atorvastatin titration (A20/40) and against switch
to rosuvastatin 10/20 mg (R10/20) in Portuguese CHD patients who are currently
above LDL-C goal (2.5mmol/L). METHODS: The analysis was based on a previ-
ously published Markov model, employed to evaluate the life-time costs and health
outcomes, including life-years (LY) and quality adjusted life-years (QALY). The
model incorporated Framingham risk equations, Portuguese population character-
istics, CHD event rates, quality of life estimates, local resource use and due unit
costs. RESULTS: From 18 CHD patient risk profiles, discounted lifetime costs per
patient with A20/40, R10/20 and A10/20EZ10 treatment were €20,987, €23,134 and
€25,476, respectively. Average gain with A10/20EZ10 were 0.43 LY and 0.17 QALY
versus A20/40; and 0.38 LY and 0.15 QALY versus R10/20. Thus, the incremental
costs per QALY gained by switching patients from A10/20 to A20/40EZ10 were
€26,435 and €15,907 against titrating to A20/40 and switch to R10/20, respectively.
Based on the Portuguese CE acceptability frontier with a willingness-to-pay value
of €30.000/QALY gained, A10/20EZ10 is projected to be CE for CHD patients on
secondary prevention. CONCLUSIONS: In the Portuguese CHD patients not at
LDL-C goal treated with A10/20, adding EZ10 is CE when compared with atorvasta-
tin titration or switching to rosuvastatin. Moreover, the expected erosion of atorv-
astatin generics’ price will favor CE ratio of A10/20EZ10 versus R10/20 switch.
Thus, ezetimibe is effective in lowering LDL-C, and based on the analysis con-
ducted, is projected to reduce CV events, improve quality of life, and is cost-effec-
tive by commonly used criteria in Portugal.
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OBJECTIVES: Recently, the first single pill (SPC) triple-combination antihyperten-
sive therapy with valsartan(VAL), amlodipine(AML) and hydrochlorothiazide(H-
CTZ) has been available. The aim of this study is to compare the cost-utility of
single pill triple combination with each of the dual combinations deriving from the
same components in patients with moderate to severe hypertension. This is the
first study to evaluate the CUA of this SPC. METHODS: A Markov model with eight
health states was constructed. The short-term effect of antihypertensive treat-
ment on blood pressure was extrapolated through the Hellenic SCORE and
Framingham risk equations in order to estimate the long-term survival and qual-
ity-adjusted life-years (QALYs). Pharmaceutical cost was extracted from the official
price bulletins. Cost of adverse events was derived from international literature,
reflecting €2012. Outcomes and costs were evaluated over lifetime, divided into
annual cycles and were discounted at 3.0%. The analysis was conducted from a
Greek third-party-payer perspective. RESULTS: The cost of treatment with triple
combination was estimated at €17,499 in comparison to €18,203 for AML/VAL,
€16,069 for VAL/HCTZ and €11,945 for AML/HCTZ. The QALYs of the triple combi-
nation were 12.76 vs. 12.64, 12.61 and 12.38 of double combinations respectively,
resulting in incremental QALYs gained of triple vs. double combination in 0.12, 0.15
and 0.38 respectively. The incremental cost-effectiveness ratio (ICER) per QALY
gained with the triple combination versus VAL/HCTZ and AML/HCTZ was far lower
than the Greek GDP per capita (9,649€, 14,581€, respectively), while the triple com-
bination was found to be dominant in comparison with AML/VAL. Extensive sen-
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sitivity analyses proved the robustness of the results. With a probability of exceed-
ing 90%, the triple combination is cost effective with an incremental cost
effectiveness ratio (ICER) threshold of less than 20,000 €/QALY.CONCLUSIONS:The
single pill triple combination therapy with AML/VAL/HCTZ is a highly cost-effec-
tive antihypertensive choice for the treatment of moderate to severe hypertension.
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OBJECTIVES: To undertake an economic evaluation of rivaroxaban relative to stan-
dard care with injectable heparins (enoxaparin) followed by dose adjusted vitamin-
K-antagonists for the treatment of deep vein thrombosis (DVT). METHODS: An
international Markov model designed to reflect the management and complica-
tions of DVT in the course of three month cycles, up to death, was locally adapted.
It comprises twelve health states and allows for the comparison of rivaroxaban
against standard treatment in the six-month acute treatment phase. Baseline
event rates and the relative treatment effect of rivaroxaban (HRs) were derived
from the whole study population of the EINSTEIN DVT trial. Utility values were
based on the published literature. Cost data reflect the year 2012 and were ex-
tracted from local sources. The incremental cost-effectiveness ratio (ICER) was
calculated with quality-adjusted-life-years (QALYs) gained as the outcome mea-
sure. One-way sensitivity analyses and probabilistic analysis was undertaken to
deal with uncertainty. The analysis was undertaken from a payer perspective and
all costs and outcomes were discounted at 3.5%. RESULTS: The analysis showed
that the average total cost of 6-month rivaroxaban-treated patients was €170
higher compared to patients treated with the standard care. Rivaroxaban was as-
sociated with additional drug costs (€457), however these were partially offset by
reduced monitoring costs (€257). Moreover, rivaroxaban was associated with a
small QALY increment (0.019) and the ICER was calculated at €8,795 per QALY
gained. Sensitivity analysis showed that the base case ICER was most sensitive to
HRs for recurrent venous thromboembolism and major bleeds. Excluding the cost
of rivaroxaban, the model was also relatively sensitive to mean cohort age. Proba-
bilistic analysis revealed that the likelihood of rivaroxaban being cost-effective at a
threshold of €30,000/QALY was 89% and at €40,000 was 93%. CONCLUSIONS: Rivar-
oxaban may represent a cost-effective new alternative for the management of DVT
in Greece.
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OBJECTIVES: Ivabradine is a new therapeutic option for symptomatic heart failure
(HF) patients with reduced ejection fraction in sinus rhythm. SHIFT was an inter-
national, phase III, multicenter, randomized trial comparing ivabradine added to
standard care (SC) with SC alone in heart failure patients. Cardiovascular death or
hospitalization due to worsening HF was observed significantly less with ivabra-
dine than with placebo (hazard ratio 0.82, 95%CI: 0.75-0.90, P0.0001). In this study
we used Turkish data to evaluate cost effectiveness of ivabradine added to SC vs SC
alone in HF patients in a Turkish setting from national health care provider
perspective. METHODS: We used a two-state Markov cohort model (alive vs dead)
with a one-month cycle. Ivabradine added to SC was compared with SC alone based
on raw data of SHIFT trial. Health benefit modeled was life-years gained. Time
horizon was “lifetime”. The model considers direct costs only. Health care re-
sources were hospitalization, medications, HF management (1USD 1.7681TL; Feb
2012) and costs associated are collected from Ministry of Health and National Social
Security Organization lists. GDP per capita is 10.444USD in Turkey (2011). One-way
and probabilistic sensitivity analyses were performed with changes in model pa-
rameters, ie baseline heart rate, NYHA class, hospitalization rate etc. RESULTS:
Total costs were 17.225USD for ivabradine added to SC and 13.754USD for SC alone.
Life-years gained with ivabradine added to SC were 0.384; incremental cost-effec-
tiveness ratio was calculated as 9.040USD/LY gained. ICER value was robust to most
model parameters, but was sensitive to baseline heart rate and hospitalization rate
ratio. CONCLUSIONS: Ivabradine added to SC was cost effective in HF patients in
sinus rhythm in a Turkish setting (lower than GDP per capita in Turkey and in line
with WHO recommendations). This finding is based on significant decrease in
mortality and hospitalizations and related costs provided with ivabradine.
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OBJECTIVES: To compare the cost effectiveness of adding ezetimibe on top of
atorvastatin therapy vs. doubling of atorvastatin dose for high risk patients who
failed to reach target LDL cholesterol (LDL-C) levels on their current atorvastatin
dose. METHODS: A previously developed Markov model was utilized to evaluate
cost and health outcomes converted into quality adjusted life-years (QALY). The
lipid-lowering effects of the addition of ezetimibe (10mg) on top of atorvastatin
(20mg) (EZA) vs. doubling of existing atorvastatin (10 or20mg to 20 or 40 mg) (2A)
doses were estimated from clinical trial data. High risk cohort was defined as those
with established coronary heart disease (CHD) and/or diabetes. Patient profile data
were generated based on the LTAP-2 study in Brazil. Costs of acute and long-term
care for CHD events and treatments were calculated in Brazilian Reals (R$).
RESULTS:Discounted costs and QALYs ranged from R$ 13,576 to R$ 57,273 and 5.99
to 15.59 respectively for 2A arm whereas ranges for discounted costs and QALYs
were R $15,673 to R$ 60,735 and 6.16 to 15.64 respectively for EZA among 54
patients with CHD and/or diabetes. Incremental cost-effectiveness ratios (ICERs)
comparing EZA vs. 2A were estimated to range between R$ 13,392 to R$ 75,883
(ICER exceeded R$ 60,000 only for 4 patient profiles). These results suggest that
EZA was cost-effective against 2A at a threshold of 3 times Brazilian per capita
GDP (R$ 60,000) for majority of the patients (50 out of 54 patient profiles). In
addition, for patients with CHD and diabetes, EZA was highly cost-effective (ICER
less than Brazilian GDP per capita R$ 20,000) against 2A. CONCLUSIONS: Results
suggested that adding ezetimibe to atorvastatin among high risk patients who
were not at LDL-C goal could be a cost-effective treatment strategy when compared
to doubling of atorvastatin dose.
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Heart failure (HF) represents a significant economic burden worldwide with hospi-
talizations as main cost driver. Ivabradine, has been granted in the treatment of
symptomatic heart failure patients, based on SHIFT trial. OBJECTIVES: To evaluate
the cost-effectiveness of Ivabradine on top of standard care of heart failure versus
standard care alone in Thai patients from the national health care perspective.
METHODS: An economic evaluation based on clinical benefits observed and re-
sources consumed during the SHIFT, a randomized placebo-controlled trial, with
ivabradine on top of standard care compared to standard care alone with a mean
follow up of 22.9 months. The principal results were -18% and -26% relative risk
reduction from cardiovascular death or hospitalization for heart failure and hos-
pitalization for worsening heart failure. Risk equations were built based on SHIFT
data, adjusting clinical benefits to Thai patient profile obtained from literature
review. Drug local costs were the lowest median prices from ministry of public
health database. Hospital costs were extracted from a public hospital database on
HF admission during January-December 2011 representing 1,276 patient-treatment
days, with mean hospital charges combined in Thai baht(THB). The incremental
cost-effectiveness ratios (ICER) were calculated and expressed in cost/life years
gained (LYG) and cost/Quality-Adjusted Life Years gained (QALYg). Probabilistic
sensitivity analysis was performed. RESULTS: Mean total cost [95% CI], LY and
QALY gained were 224,880 [220,470 - 228,978] THB, 2.12 LY and 1.52 QALY respec-
tively, for Thai heart failure patients treated by ivabradine on top of standard care,
while 227,884 [222,736-232,667] THB, 2.09 LY and 1.49 QALY respectively for pa-
tients treated by standard care alone. As results, ivabradine on top of standard care
provided an ICER of 134,281THB/LYG and 109,415THB/QALYg compared with stan-
dard care alone. CONCLUSIONS: Ivabradine on top of standard care treatment for
Thai heart failure patient is dominant as compared with standard care alone re-
sulting in LYG, QALY gains of 134,281THB and 109,415 THB.
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OBJECTIVES: To evaluate cost effectiveness of amlodipine (aml) / valsartan (val) /
hydrochlorothiazide (hctz) single pill combination(SPC) versus aml/val or val/hctz
SPCs. METHODS: The efficacy results of the SPCs evaluated will be obtained from a
randomized controlled study conducted by Calhoun DA et.al. Price of the SPCs
evaluated will be obtained from price list of the Ministry of Health of Turkey.
Aml/Val 10/320 mg is not available in Turkish market, therefore its price will be
estimated by using regression model based on the prices of the other available
antihypertensives in the Turkey. Cost-effectiveness (CE) ratio for each SPC was
calculated and SPCs will be compared in terms of incremental cost-effectiveness
ratio (ICER). RESULTS: The ratio of patients achieving blood pressure (BP) rates
were 70.8%, 54.1% and 48.3% with aml/val/hctz 10/320/25 mg, aml/val 10/320 mg
and val/hctz 320/25 mg, respectively (1). The drug costs of the aml/val/hctz 10/
320/25 mg, aml/val 10/320 mg and val/hctz 320/25 mg 9-weeks treatments for 100
patients are 14,161 TL, 11,692 TL and 5,962 TL, respectively. The CE ratios of aml/
val/hctz 10/320/25 mg, aml/val 10/320 mg and val/hctz 320/25 mg are calculated as
2.0, 2.16 and 1.23 respectively. Thirty-day adjusted ICERs of aml/val/hctz 10/320/25
mg are 70.40 TL and 173.52 per percentage of patients achieving BP targets versus
aml/val 10/320 mg and val/hctz 320/25 mg, respectively, whereas it is 470.44 TL with
aml/val 10/320 mg versus val/hctz 320/25 mg. CONCLUSIONS: Although there is no
formal threshold for ICER per percentage of patients achieving BP targets in Turkey,
reimbursement of aml/val/hctz 10/320/25 mg seems to be affordable.
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